UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________

Current Report

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1, 2021 (November 1, 2021)
 
______________
 
MOLINA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-31719
13-4204626
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
______________
 
200 Oceangate, Suite 100, Long Beach, California 90802
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (562) 435-3666
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 Par Value
MOH
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.
☐
Item 7.01.  Regulation FD Disclosure.

Note: The information furnished herewith pursuant to Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed by Molina Healthcare, Inc. (the “Company”) under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.  The furnishing of this report is not intended to constitute a determination by the Company that the information is material or that dissemination of the information is required by Regulation FD.

Uses and Definitions of Non-GAAP Financial Measures

The financial data provided to potential investors in connection with the Offering (as defined in Item 8.01 of this report) includes non-GAAP financial measures, including EBITDA and Adjusted EBITDA (collectively, the “Non-GAAP Financial Measures”). The Non-GAAP Financial Measures are supplemental measures of the Company’s performance that are not required by, or presented in accordance with, generally accepted accounting principles in the U.S. (“GAAP”).  The Company believes that the Non-GAAP Financial Measures are useful supplemental measures to investors in comparing its performance to the performance of other public companies in the health care industry.
 
The Company defines EBITDA as net income adjusted for interest, taxes, depreciation and amortization.

The Company defines Adjusted EBITDA as EBITDA adjusted for non-cash stock-based compensation expense, transaction costs and other non-cash or non-recurring charges.

EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP. Some of these limitations are that EBITDA and Adjusted EBITDA:
•
exclude certain tax payments that may represent a reduction in cash available to the Company;
•
do not reflect the Company’s cash expenditures, or future requirements, for capital expenditures or contractual commitments;
•
do not reflect changes in, or cash requirements for, the Company’s working capital needs;
•
do not reflect the significant interest expense, or the cash requirements, necessary to service interest or principal payments on the Company’s debt;
•
although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements; and
•
may be calculated differently than other companies in the Company’s industry, limiting their usefulness as comparative measures.

-2-
In addition to the foregoing, Adjusted EBITDA adjusts for certain exceptional items that reflect cash payments that were made or received, or will be made or received, in the future.
 
Because of these limitations, the Non-GAAP Financial Measures should not be considered as measures of discretionary cash available to the Company to invest in the growth of the Company’s business. The Company compensates for these limitations by relying primarily on its GAAP results and using the Non-GAAP Financial Measures only on a supplemental basis.
 
The following EBITDA and Adjusted EBITDA information was provided to potential investors in connection with the Offering:

   
Year Ended
December 31,
    
Nine Months
Ended September 30,
(unaudited)
  
   
2018
    
2019
    
2020
    
2020
    
2021
  
   
(dollars in millions)
  
Net income                                                                
  
$
707
    
$
737
    
$
673
    
$
639
    
$
556
  
Adjustments:
                                        
Depreciation, and amortization of intangible assets and capitalized software
    
118
      
89
      
88
      
64
      
96
  
Interest expense                                                              
    
115
      
87
      
102
      
72
      
90
  
Income tax expense                                                              
    
292
      
235
      
288
      
271
      
183
  
EBITDA                                                                
  
$
1,232
    
$
1,148
    
$
1,151
    
$
1,046
    
$
925
  
Stock-based compensation
    
27
      
39
      
57
      
43
      
49
  
Non-cash or non-recurring charges(a)
    
44
      
8
      
6
      
10
      
6
  
Transaction costs(b)                                                                
    
10
      
-
      
-
      
–
      
–
  
Adjusted EBITDA
 
$
1,313
    
$
1,195
    
$
1,214
    
$
1,099
    
$
980
  

(a)
Represents non-cash or non-recurring charges of (i) $44 million related to restructuring charges, loss on sale of subsidiaries, net of gain, and loss on debt extinguishment for the year ended December 31, 2018, (ii) $8 million related to loss on debt extinguishment for the year ended December 31, 2019, (iii) $6 million related to the premium deficiency reserve in Puerto Rico for  the year ended December 31, 2020, (iv) $10 million related to the premium deficiency reserve in Puerto Rico for the nine months ended September 30, 2020, and (v) $6 million related to the premium deficiency reserve in Puerto Rico for the nine months ended September 30, 2021.

(b)
Represents transaction costs related to repayment of the Company’s 1.625% convertible senior notes due 2044 that were settled in 2018.

Item 8.01.  Other Events.
 
On November 1, 2021, the Company issued a press release announcing it intends to privately offer (the “Offering”), subject to market and other conditions, $750 million aggregate principal amount of senior notes due 2032 (the “Notes”). The Notes are to be offered and sold only to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act, and to certain persons outside the United States in reliance on Regulation S under the Securities Act. The full text of the press release is attached as Exhibit 99.1.
 
-3-
Item 9.01.  Financial Statements and Exhibits.
 
(d)            Exhibits:

Exhibit
No.
Description
   
   
104
Cover page information from Molina Healthcare, Inc.’s Current Report on Form 8-K filed on November 1, 2021 formatted in iXBRL (Inline Extensible Business Reporting Language)

-4-
 SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 

MOLINA HEALTHCARE, INC.  
       
Date: November 1, 2021
By:
/s/ Jeff D. Barlow
  
   
Jeff D. Barlow,
Chief Legal Officer and Secretary
  



-5-